Unraveling the pathogenesis of MDS: The NLRP3 inflammasome and pyroptosis drive the MDS phenotype

Frontiers in Oncology

Volumn 6, Issue JUN, 2016, Pages

  Sallman, David A ^a   Cluzeau, Thomas ^b,c,d,e   Basiorka, Ashley A ^a   List, Alan ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY HOSPITAL OF NICE   (France)

^c UNIVERSITÉ CÔTE D'AZUR   (France)

^d CENTRE MÉDITERRANÉEN DE MÉDECINE MOLÉCULAIRE C3M   (France)

^e French Group of Myelodysplasia   (France)

Author keywords

Inflammasome; MDS; NLRP3; Pyroptosis; S100A9; TLR

Indexed keywords

ALARMIN; BETA CATENIN; CALGRANULIN A; CALGRANULIN B; CASPASE 8; CASPASE 9; CD33 ANTIGEN; CRYOPYRIN; DEATH RECEPTOR; FLICE INHIBITORY PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; PATHOGEN ASSOCIATED MOLECULAR PATTERN; PATTERN RECOGNITION RECEPTOR; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNINDEXED DRUG;

ACUTE MYELOBLASTIC LEUKEMIA; APOPTOSIS; BONE MARROW; CELL DEATH; CELL DIFFERENTIATION; DNA REPAIR; DYSPLASIA; EPIGENETICS; GENE MUTATION; GENETIC HETEROGENEITY; HEMATOPOIESIS; HUMAN; IMMUNORECEPTOR TYROSINE BASED INHIBITION MOTIF; INNATE IMMUNITY; MYELODYSPLASTIC SYNDROME; PROTEIN EXPRESSION; PYROPTOSIS; REVIEW;

EID: 84982832820     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2016.00151     Document Type: Review

References (67)

1. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol (2004) 5(10):987-95. doi:10.1038/ni1112
2. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat Immunol (2010) 11(5):373-84. doi:10.1038/ni.1863
3. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell (2006) 124(4):783-801. doi:10.1016/j.cell.2006.02.015
4. Kagan JC, Medzhitov R. Phosphoinositide-mediated adaptor recruitment controls toll-like receptor signaling. Cell (2006) 125(5):943-55. doi:10.1016/j.cell.2006.03.047
5. Rowe DC, McGettrick AF, Latz E, Monks BG, Gay NJ, Yamamoto M, et al. The myristoylation of TRIF-related adaptor molecule is essential for toll-like receptor 4 signal transduction. Proc Natl Acad Sci U S A (2006) 103(16):6299-304. doi:10.1073/pnas.0510041103
6. Kawagoe T, Sato S, Matsushita K, Kato H, Matsui K, Kumagai Y, et al. Sequential control of toll-like receptor-dependent responses by IRAK1 and IRAK2. Nat Immunol (2008) 9(6):684-91. doi:10.1038/ni.1606
7. Bhoj VG, Chen ZJ. Ubiquitylation in innate and adaptive immunity. Nature (2009) 458(7237):430-7. doi:10.1038/nature07959
8. Deng L, Wang C, Spencer E, Yang L, Braun A, You J, et al. Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell (2000) 103(2):351-61. doi:10.1016/S0092-8674(00)00126-4
9. Metcalf D. Hematopoietic cytokines. Blood (2008) 111(2):485-91. doi:10.1182/blood-2007-03-079681
10. Nagai Y, Garrett KP, Ohta S, Bahrun U, Kouro T, Akira S, et al. Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment. Immunity (2006) 24(6):801-12. doi:10.1016/j.immuni.2006.04.008
11. Schmid MA, Takizawa H, Baumjohann DR, Saito Y, Manz MG. Bone marrow dendritic cell progenitors sense pathogens via toll-like receptors and subsequently migrate to inflamed lymph nodes. Blood (2011) 118(18):4829-40. doi:10.1182/blood-2011-03-344960
12. Mohrin M, Bourke E, Alexander D, Warr MR, Barry-Holson K, Le Beau MM, et al. Hematopoietic stem cell quiescence promotes error-prone DNA repair and mutagenesis. Cell Stem Cell (2010) 7(2):174-85. doi:10.1016/j.stem.2010.06.014
13. Raaijmakers MH, Mukherjee S, Guo S, Zhang S, Kobayashi T, Schoonmaker JA, et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature (2010) 464(7290):852-7. doi:10.1038/nature0885
14. Takizawa H, Boettcher S, Manz MG. Demand-adapted regulation of early hematopoiesis in infection and inflammation. Blood (2012) 119(13):2991-3002. doi:10.1182/blood-2011-12-380113
15. Maratheftis CI, Andreakos E, Moutsopoulos HM, Voulgarelis M. Toll-like receptor-4 is up-regulated in hematopoietic progenitor cells and contributes to increased apoptosis in myelodysplastic syndromes. Clin Cancer Res (2007) 13(4):1154-60. doi:10.1158/1078-0432.CCR-06-2108
16. Starczynowski DT, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi A, et al. Identification of miR-145 and miR-146a as mediators of the 5q-syndrome phenotype. Nat Med (2010) 16(1):49-58. doi:10.1038/nm.2054
17. Pellagatti A, Cazzola M, Giagounidis A, Perry J, Malcovati L, Della Porta MG, et al. Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. Leukemia (2010) 24(4):756-64. doi:10.1038/leu.2010.31
18. Rhyasen GW, Bolanos L, Fang J, Jerez A, Wunderlich M, Rigolino C, et al. Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome. Cancer Cell (2013) 24(1):90-104. doi:10.1016/j.ccr.2013.05.006
19. Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MA, et al. Mrp8 and Mrp14 are endogenous activators of toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med (2007) 13(9):1042-9. doi:10.1038/nm1638
20. Ehrchen JM, Sunderkotter C, Foell D, Vogl T, Roth J. The endogenous toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol (2009) 86(3):557-66. doi:10.1189/jlb.1008647
21. Cluzeau T, McGraw KL, Irvine B, Masala E, Ades L, Basiorka AA, et al. The proinflammatory protein S100A9 suppresses erythropoietin elaboration in patients with myelodysplastic syndromes. Blood (2015) 126(23):355.
22. Turovskaya O, Foell D, Sinha P, Vogl T, Newlin R, Nayak J, et al. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis (2008) 29(10):2035-43. doi:10.1093/carcin/bgn188
23. Cheng P, Corzo CA, Luetteke N, Yu B, Nagaraj S, Bui MM, et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med (2008) 205(10):2235-49. doi:10.1084/jem.20080132
24. Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, Srikrishna G. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol (2008) 181(7):4666-75. doi:10.4049/jimmunol.181.7.4666
25. Kristinsson SY, Bjorkholm M, Hultcrantz M, Derolf AR, Landgren O, Goldin LR. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J Clin Oncol (2011) 29(21):2897-903. doi:10.1200/JCO.2011.34.8540
26. Chen X, Eksioglu EA, Zhou J, Zhang L, Djeu J, Fortenbery N, et al. Induction of myelodysplasia by myeloid-derived suppressor cells. J Clin Invest (2013) 123(11):4595-611. doi:10.1172/JCI67580
27. Verschoor CP, Johnstone J, Millar J, Dorrington MG, Habibagahi M, Lelic A, et al. Blood CD33(+)HLA-DR(-) myeloid-derived suppressor cells are increased with age and a history of cancer. J Leukoc Biol (2013) 93(4):633-7. doi:10.1189/jlb.0912461
28. Schneider RK, Schenone M, Ferreira MV, Kramann R, Joyce CE, Hartigan C, et al. Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9. Nat Med (2016) 22(3):288-97. doi:10.1038/nm.4047
29. Brennan MA, Cookson BT. Salmonella induces macrophage death by caspase-1-dependent necrosis. Mol Microbiol (2000) 38(1):31-40. doi:10.1046/j.1365-2958.2000.02103.x
30. Masters SL, Gerlic M, Metcalf D, Preston S, Pellegrini M, O'Donnell JA, et al. NLRP1 inflammasome activation induces pyroptosis of hematopoietic progenitor cells. Immunity (2012) 37(6):1009-23. doi:10.1016/j.immuni.2012.08.027
31. Cookson BT, Brennan MA. Pro-inflammatory programmed cell death. Trends Microbiol (2001) 9(3):113-4. doi:10.1016/S0966-842X(00)01936-3
32. Bergsbaken T, Fink SL, Cookson BT. Pyroptosis: host cell death and inflammation. Nat Rev Microbiol (2009) 7(2):99-109. doi:10.1038/nrmicro2070
33. Simard JC, Cesaro A, Chapeton-Montes J, Tardif M, Antoine F, Girard D, et al. S100A8 and S100A9 induce cytokine expression and regulate the NLRP3 inflammasome via ROS-dependent activation of NF-kappaB(1.). PLoS One (2013) 8(8):e72138. doi:10.1371/journal.pone.0072138
34. Velegraki M, Papakonstanti E, Mavroudi I, Psyllaki M, Tsatsanis C, Oulas A, et al. Impaired clearance of apoptotic cells leads to HMGB1 release in the bone marrow of patients with myelodysplastic syndromes and induces TLR4-mediated cytokine production. Haematologica (2013) 98(8):1206-15. doi:10.3324/haematol.2012.064642
35. Baroja-Mazo A, Martin-Sanchez F, Gomez AI, Martinez CM, Amores-Iniesta J, Compan V, et al. The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response. Nat Immunol (2014) 15(8):738-48. doi:10.1038/ni.2919
36. Basiorka A, McGraw K, Eksioglu E, Chen X, Johnson J, Padron E, et al. 32 Activation of redox-sensitive inflammasomes underlies the biological phenotype of myelodysplastic syndromes. Leuk Res (2015) 39:S14. doi:10.1016/S0145-2126(15)30033-3
37. Holl TM, Kelsoe G. Outside influence: TLRs direct hematopoietic cell fates. Immunity (2006) 24(6):667-9. doi:10.1016/j.immuni.2006.06.007
38. Esplin BL, Shimazu T, Welner RS, Garrett KP, Nie L, Zhang Q, et al. Chronic exposure to a TLR ligand injures hematopoietic stem cells. J Immunol (2011) 186(9):5367-75. doi:10.4049/jimmunol.1003438
39. Fink SL, Cookson BT. Caspase-1-dependent pore formation during pyroptosis leads to osmotic lysis of infected host macrophages. Cell Microbiol (2006) 8(11):1812-25. doi:10.1111/j.1462-5822.2006.00751.x
40. Zhang W, Hirschler-Laszkiewicz I, Tong Q, Conrad K, Sun SC, Penn L, et al. TRPM2 is an ion channel that modulates hematopoietic cell death through activation of caspases and PARP cleavage. Am J Physiol Cell Physiol (2006) 290(4):C1146-59. doi:10.1152/ajpcell.00205.2005
41. Zhong Z, Zhai Y, Liang S, Mori Y, Han R, Sutterwala FS, et al. TRPM2 links oxidative stress to NLRP3 inflammasome activation. Nat Commun (2013) 4:1611. doi:10.1038/ncomms2608
42. Kajla S, Mondol AS, Nagasawa A, Zhang Y, Kato M, Matsuno K, et al. A crucial role for Nox 1 in redox-dependent regulation of Wnt-beta-catenin signaling. FASEB J (2012) 26(5):2049-59. doi:10.1096/fj.11-196360
43. Galluzzi L, Maiuri MC, Vitale I, Zischka H, Castedo M, Zitvogel L, et al. Cell death modalities: classification and pathophysiological implications. Cell Death Differ (2007) 14(7):1237-43. doi:10.1038/sj.cdd.4402148
44. Schneider P, Tschopp J. Apoptosis induced by death receptors. Pharm Acta Helv (2000) 74(2-3):281-6. doi:10.1016/S0031-6865(99)00038-2
45. Konopleva M, Zhao S, Xie Z, Segall H, Younes A, Claxton DF, et al. Apoptosis. Molecules and mechanisms. Adv Exp Med Biol (1999) 457:217-36. doi:10.1007/978-1-4615-4811-9_24
46. Ganser A, Seipelt G, Hoelzer D. The role of GM-CSF, G-CSF, interleukin-3, and erythropoietin in myelodysplastic syndromes. Am J Clin Oncol (1991) 14(Suppl 1):S34-9. doi:10.1097/00000421-199112001-00007
47. Smith MA, Smith JG. The occurrence subtype and significance of haemopoietic inhibitory T cells (HIT cells) in myelodysplasia: an in vitro study. Leuk Res (1991) 15(7):597-601. doi:10.1016/0145-2126(91)90028-R
48. Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell (1994) 76(6):959-62. doi:10.1016/0092-8674(94)90372-7
49. Nagata S, Golstein P. The Fas death factor. Science (1995) 267(5203):1449-56. doi:10.1126/science.7533326
50. Raza A, Gezer S, Mundle S, Gao XZ, Alvi S, Borok R, et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood (1995) 86(1):268-76.
51. Claessens YE, Park S, Dubart-Kupperschmitt A, Mariot V, Garrido C, Chretien S, et al. Rescue of early-stage myelodysplastic syndrome-deriving erythroid precursors by the ectopic expression of a dominant-negative form of FADD. Blood (2005) 105(10):4035-42. doi:10.1182/blood-2004-08-3166
52. Benesch M, Platzbecker U, Ward J, Deeg HJ, Leisenring W. Expression of FLIP(Long) and FLIP(Short) in bone marrow mononuclear and CD34+ cells in patients with myelodysplastic syndrome: correlation with apoptosis. Leukemia (2003) 17(12):2460-6. doi:10.1038/sj.leu.2403180
53. Kerbauy DM, Lesnikov V, Abbasi N, Seal S, Scott B, Deeg HJ. NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs). Blood (2005) 106(12):3917-25. doi:10.1182/blood-2005-04-1424
54. Ohsumi Y. Molecular dissection of autophagy: two ubiquitin-like systems. Nat Rev Mol Cell Biol (2001) 2(3):211-6. doi:10.1038/35056522
55. He C, Klionsky DJ. Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet (2009) 43:67-93. doi:10.1146/annurev-genet-102808-114910
56. Geng J, Klionsky DJ. The Atg8 and Atg12 ubiquitin-like conjugation systems in macroautophagy. 'Protein modifications: beyond the usual suspects' review series. EMBO Rep (2008) 9(9):859-64. doi:10.1038/embor.2008.163
57. Rosenfeldt MT, Ryan KM. The multiple roles of autophagy in cancer. Carcinogenesis (2011) 32(7):955-63. doi:10.1093/carcin/bgr031
58. Rosenfeldt MT, Ryan KM. The role of autophagy in tumour development and cancer therapy. Expert Rev Mol Med (2009) 11:e36. doi:10.1017/S1462399409001306
59. Radogna F, Dicato M, Diederich M. Cancer-type-specific crosstalk between autophagy, necroptosis and apoptosis as a pharmacological target. Biochem Pharmacol (2015) 94(1):1-11. doi:10.1016/j.bcp.2014.12.018S0006-2952(14)00732-1
60. Mathew R, White E. Autophagy in tumorigenesis and energy metabolism: friend by day, foe by night. Curr Opin Genet Dev (2011) 21(1):113-9. doi:10.1016/j.gde.2010.12.008S0959-437X(11)00002-5
61. Mortensen M, Soilleux EJ, Djordjevic G, Tripp R, Lutteropp M, Sadighi-Akha E, et al. The autophagy protein Atg7 is essential for hematopoietic stem cell maintenance. J Exp Med (2011) 208(3):455-67. doi:10.1084/jem.20101145
62. Youle RJ, Narendra DP. Mechanisms of mitophagy. Nat Rev Mol Cell Biol (2011) 12(1):9-14. doi:10.1038/nrm3028
63. Farquhar MJ, Bowen DT. Oxidative stress and the myelodysplastic syndromes. Int J Hematol (2003) 77(4):342-50. doi:10.1007/BF02982641
64. Houwerzijl EJ, Pol HW, Blom NR, van der Want JJ, de Wolf JT, Vellenga E. Erythroid precursors from patients with low-risk myelodysplasia demonstrate ultrastructural features of enhanced autophagy of mitochondria. Leukemia (2009) 23(5):886-91. doi:10.1038/leu.2008.389
65. Shi CS, Kehrl JH. MyD88 and Trif target Beclin 1 to trigger autophagy in macrophages. J Biol Chem (2008) 283(48):33175-82. doi:10.1074/jbc.M804478200
66. Mills KI, Kohlmann A, Williams PM, Wieczorek L, Liu WM, Li R, et al. Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome. Blood (2009) 114(5):1063-72. doi:10.1182/blood-2008-10-187203
67. Watson AS, Mortensen M, Simon AK. Autophagy in the pathogenesis of myelodysplastic syndrome and acute myeloid leukemia. Cell Cycle (2011) 10(11):1719-25. doi:10.4161/cc.10.11.15673